BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price Down 6.8% - What's Next?

Key Points

• Shares fell 6.8% intraday to about $8.24 (low $8.21) on light volume of 111,990 shares versus an average of 280,972, while the 50‑day SMA sits at $9.93 and market cap is $662.73 million.
• Analysts show a consensus of "Moderate Buy" with an average price target of $26 (three Buys, one Sell), and individual targets as high as $29 from HC Wainwright.
• Institutional investors own roughly 54.89% of the stock, with notable position increases by Armistice Capital, Laurion Capital, Paradigm Biocapital and new stakes from Catalio and Goldman Sachs.

Shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT - Get Free Report) traded down 6.8% during mid-day trading on Friday . The stock traded as low as $8.21 and last traded at $8.2440. 111,990 shares changed hands during trading, a decline of 60% from the average session volume of 280,972 shares. The stock had previously closed at $8.85.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Weiss Ratings assumed coverage on BridgeBio Oncology Therapeutics in a report on Wednesday, January 14th. They set a "sell (d+)" rating for the company. Stifel Nicolaus assumed coverage on BridgeBio Oncology Therapeutics in a report on Tuesday, February 10th. They set a "buy" rating and a $23.00 price objective for the company. Raymond James Financial raised BridgeBio Oncology Therapeutics to a "moderate buy" rating in a research report on Friday, January 9th. Finally, HC Wainwright raised their price target on BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a "buy" rating in a research report on Friday, March 6th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, BridgeBio Oncology Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $26.00.

BridgeBio Oncology Therapeutics Stock Performance

The stock has a 50-day simple moving average of $9.93. The company has a market capitalization of $662.73 million, a P/E ratio of -5.45 and a beta of 0.51.

Institutional Investors Weigh In On BridgeBio Oncology Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in BBOT. Armistice Capital LLC grew its position in shares of BridgeBio Oncology Therapeutics by 142.7% in the fourth quarter. Armistice Capital LLC now owns 1,000,000 shares of the company's stock valued at $12,520,000 after purchasing an additional 588,000 shares during the period. Laurion Capital Management LP grew its position in shares of BridgeBio Oncology Therapeutics by 40.1% in the fourth quarter. Laurion Capital Management LP now owns 1,464,938 shares of the company's stock valued at $18,341,000 after purchasing an additional 419,138 shares during the period. Catalio Capital Management LP purchased a new stake in shares of BridgeBio Oncology Therapeutics in the fourth quarter valued at $5,142,000. Paradigm Biocapital Advisors LP grew its position in shares of BridgeBio Oncology Therapeutics by 21.2% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 2,261,749 shares of the company's stock valued at $28,317,000 after purchasing an additional 395,608 shares during the period. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of BridgeBio Oncology Therapeutics in the fourth quarter valued at $1,185,000. Hedge funds and other institutional investors own 54.89% of the company's stock.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics NASDAQ: BBOT is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.